BIOMAT Database Logo BIOMAT Database Logo

Digoxin use in atrial fibrillation. 2017

Murat Biteker, and Bülent Özlek, and Eda Özlek, and Funda Sungur Biteker, and Nesrin Başaran, and Edip Guvenç Çekiç
Muğla University, Faculty of Medicine, Department of Cardiology, Turkey.

UI MeSH Term Description Entries
D002318 Cardiovascular Diseases Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM. Adverse Cardiac Event,Cardiac Events,Major Adverse Cardiac Events,Adverse Cardiac Events,Cardiac Event,Cardiac Event, Adverse,Cardiac Events, Adverse,Cardiovascular Disease,Disease, Cardiovascular,Event, Cardiac
D004077 Digoxin A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666) Digacin,Digitek,Digoregen,Digoxina Boehringer,Digoxine Nativelle,Dilanacin,Hemigoxine Nativelle,Lanacordin,Lanicor,Lanoxicaps,Lanoxin,Lanoxin-PG,Lenoxin,Mapluxin,Boehringer, Digoxina,Lanoxin PG,Nativelle, Digoxine,Nativelle, Hemigoxine
D006339 Heart Rate The number of times the HEART VENTRICLES contract per unit of time, usually per minute. Cardiac Rate,Chronotropism, Cardiac,Heart Rate Control,Heartbeat,Pulse Rate,Cardiac Chronotropy,Cardiac Chronotropism,Cardiac Rates,Chronotropy, Cardiac,Control, Heart Rate,Heart Rates,Heartbeats,Pulse Rates,Rate Control, Heart,Rate, Cardiac,Rate, Heart,Rate, Pulse
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000889 Anti-Arrhythmia Agents Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. Anti-Arrhythmia Agent,Anti-Arrhythmia Drug,Anti-Arrhythmic,Antiarrhythmia Agent,Antiarrhythmia Drug,Antiarrhythmic Drug,Antifibrillatory Agent,Antifibrillatory Agents,Cardiac Depressant,Cardiac Depressants,Myocardial Depressant,Myocardial Depressants,Anti-Arrhythmia Drugs,Anti-Arrhythmics,Antiarrhythmia Agents,Antiarrhythmia Drugs,Antiarrhythmic Drugs,Agent, Anti-Arrhythmia,Agent, Antiarrhythmia,Agent, Antifibrillatory,Agents, Anti-Arrhythmia,Agents, Antiarrhythmia,Agents, Antifibrillatory,Anti Arrhythmia Agent,Anti Arrhythmia Agents,Anti Arrhythmia Drug,Anti Arrhythmia Drugs,Anti Arrhythmic,Anti Arrhythmics,Depressant, Cardiac,Depressant, Myocardial,Depressants, Cardiac,Depressants, Myocardial,Drug, Anti-Arrhythmia,Drug, Antiarrhythmia,Drug, Antiarrhythmic,Drugs, Anti-Arrhythmia,Drugs, Antiarrhythmia,Drugs, Antiarrhythmic
D001281 Atrial Fibrillation Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the heart (HEART ATRIA). In such case, blood cannot be effectively pumped into the lower chambers of the heart (HEART VENTRICLES). It is caused by abnormal impulse generation. Auricular Fibrillation,Familial Atrial Fibrillation,Paroxysmal Atrial Fibrillation,Persistent Atrial Fibrillation,Atrial Fibrillation, Familial,Atrial Fibrillation, Paroxysmal,Atrial Fibrillation, Persistent,Atrial Fibrillations,Atrial Fibrillations, Familial,Atrial Fibrillations, Paroxysmal,Atrial Fibrillations, Persistent,Auricular Fibrillations,Familial Atrial Fibrillations,Fibrillation, Atrial,Fibrillation, Auricular,Fibrillation, Familial Atrial,Fibrillation, Paroxysmal Atrial,Fibrillation, Persistent Atrial,Fibrillations, Atrial,Fibrillations, Auricular,Fibrillations, Familial Atrial,Fibrillations, Paroxysmal Atrial,Fibrillations, Persistent Atrial,Paroxysmal Atrial Fibrillations,Persistent Atrial Fibrillations

Related Publications

Murat Biteker, and Bülent Özlek, and Eda Özlek, and Funda Sungur Biteker, and Nesrin Başaran, and Edip Guvenç Çekiç
Digoxin use in atrial fibrillation.
September 2013, Journal of the Mississippi State Medical Association,
Murat Biteker, and Bülent Özlek, and Eda Özlek, and Funda Sungur Biteker, and Nesrin Başaran, and Edip Guvenç Çekiç
Digoxin use in atrial fibrillation: a critical reappraisal.
June 2015, Lancet (London, England),
Murat Biteker, and Bülent Özlek, and Eda Özlek, and Funda Sungur Biteker, and Nesrin Başaran, and Edip Guvenç Çekiç
Digoxin and atrial fibrillation.
September 1987, Annals of internal medicine,
Murat Biteker, and Bülent Özlek, and Eda Özlek, and Funda Sungur Biteker, and Nesrin Başaran, and Edip Guvenç Çekiç
Digoxin Use and Adverse Outcomes in Patients With Atrial Fibrillation.
March 2016, Medicine,
Murat Biteker, and Bülent Özlek, and Eda Özlek, and Funda Sungur Biteker, and Nesrin Başaran, and Edip Guvenç Çekiç
[Digoxin and atrial fibrillation in 2016].
October 2016, Revue medicale suisse,
Murat Biteker, and Bülent Özlek, and Eda Özlek, and Funda Sungur Biteker, and Nesrin Başaran, and Edip Guvenç Çekiç
Role of Digoxin in Atrial Fibrillation.
August 2017, Journal of pharmacy practice,
Murat Biteker, and Bülent Özlek, and Eda Özlek, and Funda Sungur Biteker, and Nesrin Başaran, and Edip Guvenç Çekiç
Effect of Digoxin Use Among Medicaid Enrollees With Atrial Fibrillation.
May 2017, Circulation. Arrhythmia and electrophysiology,
Murat Biteker, and Bülent Özlek, and Eda Özlek, and Funda Sungur Biteker, and Nesrin Başaran, and Edip Guvenç Çekiç
Atrial fibrillation: Rate control and digoxin.
December 2007, BMJ (Clinical research ed.),
Murat Biteker, and Bülent Özlek, and Eda Özlek, and Funda Sungur Biteker, and Nesrin Başaran, and Edip Guvenç Çekiç
Persistence of digoxin effect in atrial fibrillation.
April 1973, JAMA,
Murat Biteker, and Bülent Özlek, and Eda Özlek, and Funda Sungur Biteker, and Nesrin Başaran, and Edip Guvenç Çekiç
[Weak evidence for digoxin in atrial fibrillation].
January 2011, Lakartidningen,
Copied contents to your clipboard!